One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Risk Prediction in Cardio-Oncology: Conceptual and Methodological Considerations: JACC: CardioOncology State-of-the-Art Review
doi : 10.1016/j.jaccao.2026.01.006
Volume 8, Issue 2, April 2026, Pages 101-119
Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art Review
doi : 10.1016/j.jaccao.2026.02.004
Volume 8, Issue 2, April 2026, Pages 120-136
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients
doi : 10.1016/j.jaccao.2026.01.004
Volume 8, Issue 2, April 2026, Pages 137-147
Cardiac Biomarker Complete Response in Light Chain Amyloidosis: How Much of the Heart Is Captured?
doi : 10.1016/j.jaccao.2026.02.003
Volume 8, Issue 2, April 2026, Pages 148-151
Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All
doi : 10.1016/j.jaccao.2026.03.004
Volume 8, Issue 2, April 2026, Pages 165-167
Cardiovascular Safety of T Cell Engagers: Reassuring Overall, But Not Benign for All
doi : 10.1016/j.jaccao.2026.03.004
Volume 8, Issue 2, April 2026, Pages 165-167
Myocardial Expression of PD-L1 as a Marker of Poor Prognosis in Immune Checkpoint Inhibitor–Associated Myocarditis
doi : 10.1016/j.jaccao.2026.03.006
Volume 8, Issue 2, April 2026, Pages 168-180
PD-L1 in ICI Myocarditis: When the Immune Brake Fails
doi : 10.1016/j.jaccao.2026.03.003
Volume 8, Issue 2, April 2026, Pages 181-184
Cardiovascular Adverse Events Following Bispecific T-Cell Redirecting Antibody Therapy
doi : 10.1016/j.jaccao.2026.02.001
Volume 8, Issue 2, April 2026, Pages 185-188
Carvedilol for Prevention of Chemotherapy-Induced Cardiotoxicity: Final Results of the CECCY Trial
doi : 10.1016/j.jaccao.2025.12.009
Volume 8, Issue 2, April 2026, Pages 189-191
Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity
doi : 10.1016/j.jaccao.2026.03.001
Volume 8, Issue 2, April 2026, Pages 192-194
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure
doi : 10.1016/j.jaccao.2026.03.005
Volume 8, Issue 2, April 2026, Pages 195-199
Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension
doi : 10.1016/j.jaccao.2026.02.002
Volume 8, Issue 2, April 2026, Pages 200-204
Redefining Gamification for Cardiovascular Prevention in High-Risk Cancer Survivors
doi : 10.1016/j.jaccao.2025.11.005
Volume 8, Issue 2, April 2026, Page 205
Gamification Boosts Physical Activity in Disparate Populations of Cancer Survivors
doi : 10.1016/j.jaccao.2025.12.010
Volume 8, Issue 2, April 2026, Page 206
REPLY: Next Steps for Studying Behaviorally Designed Gamification to Increase Physical Activity
doi : 10.1016/j.jaccao.2026.03.002
Volume 8, Issue 2, April 2026, Pages 207-208
Refining the Role of ERK Signaling in Anthracycline-Induced Cardiotoxicity
doi : 10.1016/j.jaccao.2025.10.005
Volume 8, Issue 2, April 2026, Page 209
